Company Filing History:
Years Active: 2013
Title: **John L Leazer, Jr: Innovator in Pharmaceutical Development**
Introduction
John L Leazer, Jr. is an accomplished inventor based in Metuchen, NJ, USA, known for his significant contribution to pharmaceutical research and development. With a focus on innovative treatments for metabolic syndrome and cognitive impairment, Leazer has made strides in the field of medicinal chemistry.
Latest Patents
Leazer holds one notable patent that centers on crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1. This invention, titled "Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole," presents potent inhibitors that are useful for treating conditions associated with Metabolic Syndrome, as well as cognitive impairment. The patent describes various pharmaceutical compositions containing these novel salts and outlines processes for their preparation, detailing their applications for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
Career Highlights
Leazer's career is marked by his role at Merck Sharp & Dohme Corporation, where he contributes to advancing pharmaceutical innovations. His work has positioned him as a key figure in the development of drugs targeting metabolic disorders, showcasing his commitment to improving patient health outcomes through innovation.
Collaborations
Throughout his career, Leazer has collaborated with esteemed colleagues such as Joseph E Lynch and Yuri Y Bereznitski. These collaborations have played a significant role in the research and development of groundbreaking pharmaceutical solutions, reflecting a strong team dynamic focused on innovation in medicine.
Conclusion
John L Leazer, Jr.'s contributions to pharmaceutical sciences highlight the importance of innovation in addressing pressing health concerns. With a patent that opens doors to novel treatments for conditions such as metabolic syndrome and cognitive impairment, Leazer continues to influence the landscape of drug development, solidifying his legacy as a dedicated inventor in the pharmaceutical industry.